[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BioMérieux\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":42},"100632425","impact-of-a-multiplex-respiratory-pcr-test-on-outcomes-for-patients-presenting-with-respiratory-illness-in-the-urgent-care-setting-a-hybrid-effectiveness-quasi-experimental-trial-100632425",false,"NCT07513519","Impact of a Multiplex Respiratory PCR Test on Outcomes for Patients Presenting With Respiratory Illness in the Urgent Care Setting: A Hybrid-Effectiveness Quasi-Experimental Trial","Inclusion Criteria:\n\n* Patients older than 1 year\n* Patients presenting with signs and symptoms of acute respiratory illness including but not limited to bronchitis, bronchiolitis, rhinitis, pharyngitis, tonsillitis, and laryngitis\n* First visit for respiratory indication within the study period\n\nExclusion Criteria:\n\n* Patients younger than 1 year\n* Patients for which there is a clinical suspicion of pneumonia (i.e., severe illness on presentation requiring hospitalization or not eligible for urgent care)\n* Patients experiencing symptoms for \\> 10 days\n* Patients with significant respiratory comorbidities, including COPD, emphysema, pulmonary fibrosis, diseases causing chronic respiratory tract inflammation, and other conditions\n* Patients with other significant oropharyngeal or upper respiratory comorbidities or conditions, including but not limited to nasal deformations, peritonsillar abscess\n* Had a previous visit for respiratory indication within the study period","ALL","1 Year",{"count":18,"type":19},800,"ESTIMATED","INTERVENTIONAL",[22],"NA","This research study will use a hybrid effectiveness-implementation type 1 design to assess effectiveness of the Spotfire R\u002FST assay in the urgent care setting. A hybrid effectiveness-implementation type 1 study primarily focuses on the effectiveness of an intervention (e.g., use of Spotfire R\u002FST) but also simultaneously allows for the collection of data on the barriers and facilitators of implementing the Spotfire R\u002FST test in the real-world urgent care setting.",[25],"Acute Respiratory Infections (ARIs)",[27,28,29,30],"SPOTFIRE","R\u002FST","BioFire","BioMérieux","RECRUITING","2026-03-30",{"date":34,"type":35},"2026-04-07","ACTUAL",{"date":37,"type":35},"2025-12-22",{"date":39,"type":19},"2026-04",{"name":30,"class":41},"INDUSTRY",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":5},"100627844","clinical-assessment-of-respiratory-events-for-kids-integrating-diagnostics-and-stewardship-100627844","NCT07453914","Clinical Assessment of Respiratory Events for Kids: Integrating Diagnostics and Stewardship","CARE4KIDS","Inclusion Criteria:\n\n* Children from 60 days until less than 18 years old with signs and\u002For symptoms leading to suspicion of Respiratory Tract Infection (RTI) and\u002For Influenza-Like Illness (ILI), such as fever (Temperature greater than or equal to 37.8°C), rhinorrhea, nasal obstruction, sneezing, sore throat of pharyngeal pain, difficulties in breathing and\u002For cough, tachypnea, shortness of breath, apnea, croup.\n* Children and his\u002Fher legal representative who provide their informed consent.\n* Patients willing to provide a Nasopharyngeal Swab (NPS).\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator\u002Fnurse results in significant immune dysfunction such as known primary immunodeficiency disorder, ongoing immunosuppressive therapy, known HIV infection, active or recent oncologic disease, transplant recipients and\u002For chronic use of immunomodulating agents,\n* Any condition that, in the opinion of the investigator\u002Fnurse, is related to severe patients requiring urgent referral who need to go on intensive care (such as patients who have a diagnosis of sepsis or septic shock,\n* Known pregnancy\n* Patients who refused to participate in the study and therefore declined Informed Consent Form.","60 Days","17 Years",{"count":53,"type":19},720,[22],"This study, called Care4Kids, aims to improve the management of respiratory infections in children visiting emergency departments. The research will evaluate the impact of using the BIOFIRE® SPOTFIRE® R\u002FST Panel, a rapid molecular point-of-care test, compared to standard care.\n\nChildren aged 2 months to 18 years with symptoms of respiratory tract infection or flu-like illness will be enrolled. After consent, participants will be randomly assigned to one of two groups:\n\n* Intervention group: The SPOTFIRE test will be performed immediately to guide treatment decisions.\n* Control group: Patients will receive standard care without the rapid test. The study will take place in three pediatric emergency departments in France, Greece, and Sweden. Up to 720 children will participate. A follow-up phone call will be made 14 days after the visit to check recovery and satisfaction.\n\nThe goal is to see whether rapid testing improves patient outcomes, reduces unnecessary treatments, and increases caregiver satisfaction.",[57,58,59],"Respiratory Tract Infections (RTI)","Influenza-like Illness","Children",[61,62,63,64,65,66,67,68,69,70,71],"Respiratory Tract Infection","Pediatric Respiratory Disease","Viral Respiratory Infection","Bacterial Respiratory Infection","children","Pediatrics","Stewardship","Diagnostic","Multicenter Study","Point Of Care Testing","multiplex Polymerase Chain Reaction.","NOT_YET_RECRUITING","2026-03-03",{"date":75,"type":35},"2026-03-06",{"date":77,"type":19},"2026-03",{"date":79,"type":19},"2026-09",{"name":30,"class":41},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":15,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100521764","lung-infection-in-icu-lung-i3-100521764","NCT06073834","LUNG INFECTION in ICU (LUNG-I3)","LUNG INFECTION in ICU","LUNG-I3","Inclusion Criteria:\n\nAll the following criteria\n\n* Age 18 years or greater\n* Severe ICU patients hospitalized for one of the above diseases:\n\n  * Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol\u002FL (\\>18 mg\u002FdL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20)\n  * Severe trauma (level I and II), Injury Severity Score ≥ 25 OR\n  * Burn with TBSA over 20%\n* NAD \\> 0.1 µg\u002Fkg\u002Fmin\n* At least 2 SOFA criteria ≥ 2 points\n\nExclusion Criteria:\n\n* Aspiration pneumonia\n* Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)\n* COPD\n* Smoke inhalation in burn patients\n* Participation in an intervention study\n* Pregnant or breastfeeding women\n* Immunocompromised patients, defined as\n\n  * patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease\n  * hematologic malignancies\n  * solid organ transplantation\n  * HIV infection with or without AIDS\n  * treatment with corticosteroids (\\> 3 months at any dosage or ≥ 1 mg\u002Fkg prednisone equivalent per day for \\> 7 day)\n  * treatment with other immunosuppressive drugs.","18 Years",{"count":91,"type":19},68,"OBSERVATIONAL","objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils",[95],"VAP - Ventilator Associated Pneumonia",[95,97,98,99,100],"Sepsis","Lung Infection","Broncho-alveolar Lavage","ICU","2025-02-10",{"date":103,"type":35},"2025-02-12",{"date":105,"type":35},"2023-12-05",{"date":107,"type":19},"2027-06",{"name":30,"class":41},1,""]